SCHEMBL18451256

SCHEMBL18451256

CC(N)c1cc(C(N)=O)ccc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 3/20 0.43
AR P10275 1/20 0.41
PARP10 Q53GL7 2/20 0.41
DPP4 P27487 2/20 0.40
ERN1 O75460 1/20 0.39
PDE2A O00408 1/20 0.39
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
MAPK1 P28482 1/20 0.38
LCK P06239 1/20 0.38
KDM4E B2RXH2 1/20 0.38
BRD4 O60885 1/20 0.38
ALDH1A1 P00352 1/20 0.38
BRPF1 P55201 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CHRNA1 P02708 1/20 0.37
CHRNG P07510 1/20 0.37
CHRNB1 P11230 1/20 0.37
CHRNB2 P17787 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18451253 1.00 PARP1 (0.43) PARP1ARPARP10DPP4ERN1
SCHEMBL3691250 0.87 SLC9A1 (0.45) PARP1ARPARP10DPP4ERN1
SCHEMBL765738 0.83 PARP1 (0.47) PARP1ARPARP10ERN1CES2
SCHEMBL27326910 0.77 MAPK1 (0.41) PARP1ARPARP10DPP4ERN1
SCHEMBL4734628 0.76 PARP1 (0.44) PARP1ARPARP10DPP4CES2
SCHEMBL289633 0.74 CES2 (0.67) PARP1ARDPP4ERN1CES2
SCHEMBL29781365 0.74 CES2 (0.67) PARP1ARDPP4ERN1CES2
SCHEMBL24959998 0.74 PARP1 (0.42) PARP1ARPARP10DPP4CES2
SCHEMBL13816274 0.73 PARP10 (0.46) PARP1PARP10MAPK1LCKKDM4E
SCHEMBL580392 0.73 PARP1 (0.48) PARP1ARERN1CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108137547-B Heterocyclic compounds useful as TNF alpha modulators 百时美施贵宝公司 2021-11-12 CN disclosed
US-10865191-B2 Heterocyclic compounds useful as modulators of TNF alpha BRISTOL-MYERS SQUIBB COMPANY (US) 2020-12-15 US disclosed
US-20180222883-A1 HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA BRISTOL MYERS SQUIBB CO (US) 2018-08-09 US disclosed
EP-3331871-A1 HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA Bristol-Myers Squibb Company (US) 2018-06-13 EP disclosed
WO-2017023905-A1 HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA BRISTOL-MYERS SQUIBB COMPANY (US) 2017-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10865191-B2 Heterocyclic compounds useful as modulators of TNF alpha TNF, TNFRSF9, TNFRSF1A PARP1 3892/4885AR 1971/4885PARP10 3923/4885
US-20180222883-A1 HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA TNF, TNFRSF9, TNFRSF1A PARP1 3892/4885AR 1971/4885PARP10 3923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.